Arabic Arabic English English French French German German
dark

Abivax Receives EMA Scientific Advice Supportive of Moving ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis

Abivax SA announced that the European Medicines Agency provided their feedback in the context of the scientific advice meeting that supports advancing ABX464 into phase 3 clinical testing for the treatment of ulcerative colitis and subsequent potential marketing authorization submission and commercialization. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

BenevolentAI announces 3-year collaboration expansion with AstraZeneca focused on systemic lupus erythematosus and heart failure

Next Post

NeonMind Appoints Canadian Medical Leader in Anesthesiology, Dr. Daniel Bainbridge, MD, FRCPC to Its Specialty Clinics Advisory Board

Related Posts
Total
0
Share